Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarría E, Schmitz N, Sureda A. Duarte RF, et al. Among authors: arranz r. J Clin Oncol. 2010 Oct 10;28(29):4492-9. doi: 10.1200/JCO.2010.29.3241. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697072
Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.
Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A, Olavarría E, Schmitz N, Sureda A, Dreger P. Duarte RF, et al. Among authors: arranz r. J Clin Oncol. 2014 Oct 10;32(29):3347-8. doi: 10.1200/JCO.2014.57.5597. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154828 No abstract available.
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, Arcese W, Browne P, Beelen D, Kobbe G, Veelken H, Arranz R, Greinix H, Lenhoff S, Poiré X, Ribera JM, Thompson J, Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Dreger P, Sureda A, Montoto S. Domingo-Domenech E, et al. Among authors: arranz r. Bone Marrow Transplant. 2021 Jun;56(6):1391-1401. doi: 10.1038/s41409-020-01197-3. Epub 2021 Jan 8. Bone Marrow Transplant. 2021. PMID: 33420392
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Sureda A, et al. Among authors: arranz r. Haematologica. 2012 Feb;97(2):310-7. doi: 10.3324/haematol.2011.045757. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993674 Free PMC article. Clinical Trial.
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.
Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Martínez C, et al. Among authors: arranz r. Ann Oncol. 2013 Sep;24(9):2430-4. doi: 10.1093/annonc/mdt206. Epub 2013 May 26. Ann Oncol. 2013. PMID: 23712545 Free article.
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Alvarez I, et al. Among authors: arranz r. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. doi: 10.1016/j.bbmt.2005.09.009. Biol Blood Marrow Transplant. 2006. PMID: 16443515 Free article. Clinical Trial.
Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, Jarque I, Caballero MD, Ferrà C, López A, García-Laraña J, Cabrera R, Carrera D, Ruiz-Romero MD, León A, Rifón J, Díaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altés A, López-Guillermo A, de la Serna J, Fernández-Rañada JM, Sierra J, Conde E; Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. Sureda A, et al. Among authors: arranz r. J Clin Oncol. 2001 Mar 1;19(5):1395-404. doi: 10.1200/JCO.2001.19.5.1395. J Clin Oncol. 2001. PMID: 11230484
Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.
Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vazquez L, Arranz R, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D; GELTAMO Group. Piñana JL, et al. Among authors: arranz r. Haematologica. 2010 Jul;95(7):1176-82. doi: 10.3324/haematol.2009.017608. Epub 2010 Jan 27. Haematologica. 2010. PMID: 20107156 Free PMC article. Clinical Trial.
Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.
Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A, Jarque I, Carreras E, Moraleda JM, Carrera D, León A, López A, Albó C, Díaz-Mediavilla J, Fernández-Abellán P, García-Ruiz JC, Hernández-Navarro F, Mataix R, Petit J, Pascual MJ, Rifón J, García-Conde J, Fernández-Rañada JM, Mateos MV, Sierra J, Conde E; GEL/TAMO Cooperative Group. Constans M, et al. Among authors: arranz r. Ann Oncol. 2003 May;14(5):745-51. doi: 10.1093/annonc/mdg206. Ann Oncol. 2003. PMID: 12702529 Free article.
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, García-Conde J, García-Laraña J, Cabrera R, Jarque I, Carrera D, García-Ruiz JC, Pascual MJ, Rifón J, Moraleda JM, Pérez-Equiza K, Albó C, Díaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marín J, Mateos MV, Fernández-Rañada JM, Sierra J, Conde E; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group. Sureda A, et al. Among authors: arranz r. Ann Oncol. 2005 Apr;16(4):625-33. doi: 10.1093/annonc/mdi119. Epub 2005 Feb 28. Ann Oncol. 2005. PMID: 15737986 Free article.
160 results